✦ LIBER ✦

Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC lung cancer working party (Belgium)

✍ Scribed by J. Klastersky; J. P. Sculier; J. P. Dumont; D. Becquart; G. Vandermoten; P. Rocmans; J. Michel; E. Longeval; O. Dalesio

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 425 KB
Volume: 56
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19850701)56:1<71::aid-cncr2820560112>3.0.co;2-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

Evaluation of synergism by a novel three

Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3

✍ Fumihiko Kanzawa; Kazuto Nishio; Kazuya Fukuoka; Minoru Fukuda; Takehiko Kunimot 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 206 KB 👁 2 views

Although the combination of cisplatin and etoposide has been used as standard therapy for small-cell lung cancer, it is difficult to demonstrate combination effects between cisplatin and etoposide in vitro. We therefore adopted a 3-dimensional (3-D) model to analyze the combination effects of antica

Combination chemotherapy with and withou

Combination chemotherapy with and without the methanol-extracted residue of bacillus calmette-guerin (MER) in extensive non-small-cell lung cancer: A prospective randomized study for the piedmont oncology association

✍ Frederick Richards II; Virginia Howard; Anita Shore; Hyman B. Muss; Douglas R. W 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB 👁 2 views

One-hundred-three patients with extensive non-small-cell lung cancer were entered into a prospective, randomized trial to determine the value of MER as an adjuvant to chemotherapy. Patients were stratified according to histology and performance status. All patients received CCNU, methotrexate, and A

A randomized trial of hybrid administrat

A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma : Results of long term follow-up

✍ Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Haruhito Kamei; Kenichi Gemba; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 1 views

## BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to

Prognostic factors for patients with sma

Prognostic factors for patients with small cell lung carcinoma : Analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

✍ M. Paesmans.; J. P. Sculier; J. Lecomte; J. Thiriaux; P. Libert; R. Sergysels; G 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views